OncoVista Innovative Therapies, Inc. (OVIT) Research

OncoVista Innovative Therapies, Inc. is a biopharmaceutical firm focused on creating highly specific treatments for cancer. Their methodology involves harnessing tumor-associated biomarkers to target these therapies. The company's investigational drug candidates include Cordycepin (OVI-123), which is currently progressing through Phase I/II clinical trials as a potential therapy for stubborn TdT-positive leukemias. Additionally, L-Nucleoside Conjugates (OVI-117) are in the pre-clinical research phase, being explored for their efficacy against colon cancer. This enterprise was established in 2004 and is based in San Antonio, Texas.

Market snapshot

Symbol
OVIT
Price
$0.00
Day change
0.00%
Market cap
$2.4K
P/E ratio
-0.00x
52-week range
0.0001-0.0004
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Anthera Pharmaceuticals, Inc. (ANTH)
  • Cotinga Pharmaceuticals Inc. (COTQF)
  • ForU Holdings, Inc. (FORU)
  • Longport, Inc. (LPTI)
  • Greenwind Holdings Inc. (NEWG)
  • Neurobiological Technologies, Inc. (NTII)
  • ONE Bio Corp. (ONBI)
  • PAO Group, Inc. (PAOG)

Open OncoVista Innovative Therapies, Inc. (OVIT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.